1. Home
  2. R vs ERAS Comparison

R vs ERAS Comparison

Compare R & ERAS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Ryder System Inc.

R

Ryder System Inc.

HOLD

Current Price

$219.83

Market Cap

6.5B

ML Signal

HOLD

Logo Erasca Inc.

ERAS

Erasca Inc.

HOLD

Current Price

$17.86

Market Cap

5.5B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
R
ERAS
Founded
1933
2018
Country
United States
United States
Employees
N/A
N/A
Industry
Rental/Leasing Companies
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
6.5B
5.5B
IPO Year
1994
2021

Fundamental Metrics

Financial Performance
Metric
R
ERAS
Price
$219.83
$17.86
Analyst Decision
Buy
Strong Buy
Analyst Count
10
12
Target Price
$213.78
$12.08
AVG Volume (30 Days)
244.4K
5.0M
Earning Date
04-23-2026
05-12-2026
Dividend Yield
1.65%
N/A
EPS Growth
7.96
36.23
EPS
11.94
N/A
Revenue
$12,665,000,000.00
N/A
Revenue This Year
$3.91
N/A
Revenue Next Year
$5.74
N/A
P/E Ratio
$18.47
N/A
Revenue Growth
0.23
N/A
52 Week Low
$130.16
$1.06
52 Week High
$230.39
$18.20

Technical Indicators

Market Signals
Indicator
R
ERAS
Relative Strength Index (RSI) 65.33 63.75
Support Level $184.78 $1.72
Resistance Level $229.19 $18.20
Average True Range (ATR) 5.55 1.30
MACD 2.52 0.01
Stochastic Oscillator 89.35 88.45

Price Performance

Historical Comparison
R
ERAS

About R Ryder System Inc.

Ryder System Inc operates in three business segments: (1) Fleet Management Solutions which provides full-service leasing and leasing with flexible maintenance options, commercial rental and maintenance services of trucks, tractors and trailers to customers; (2) Supply Chain Solutions (SCS), which provides integrated logistics solutions, including distribution management, dedicated transportation, transportation management, brokerage, e-commerce, last mile, and professional services; and (3) Dedicated Transportation Solutions (DTS), which provides turnkey transportation solutions in the U.S., including dedicated vehicles, professional drivers, management, and administrative support.

About ERAS Erasca Inc.

Erasca Inc is a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. Its focused RAS/MAPK pathway pipeline comprises modality-agnostic programs aligned with three therapeutic strategies of: targeting key upstream and downstream signaling nodes in the RAS/MAPK pathway; targeting RAS directly; and targeting escape routes that emerge in response to treatment. Its pipeline includes two clinical-stage programs (ERAS-0015, a pan-RAS molecular glue; and ERAS-4001, a pan-KRAS inhibitor), and ERAS-12, a discovery-stage program.

Share on Social Networks: